India and China, two of the world’s most populous countries and once considered difficult markets to enter, have taken significant strides as emerging markets in drug development. It is no coincidence over the last decade or more of economic liberalization, and years of unprecedented growth, that India and China are becoming a preferred clinical research destination for multinational pharmaceutical and biotechnology corporations.

The conference aims to provide a detailed analysis of what it takes to conduct clinical trials from a biopharmaceuticals and vaccines perspective in India and China, to address: risk/benefit balance; anecdotal experiences of the multinational pharmaceutical industry in India and China; selection and role of CROs; logistics of operations; clinical trials management; government policies (including IPR issues); and pharmacovigilance.

WHO SHOULD ATTEND
This program will benefit professionals involved in:

- Clinical research and development
- Clinical safety and pharmacovigilance
- Clinical supplies
- Biostatistics
- Data management
- Investigator site management
- Outsourcing management/contract research organizations (CROs)
- Project management
- Medical affairs
- R&D and strategic issues
- Regulatory affairs
- Public policy and law including intellectual property

FEATURED SPEAKERS

Kenneth I. Kaitin, PhD
Director of the Tufts Center for the Study of Drug Development
Associate Professor of Medicine
Tufts University School of Medicine, Tufts University

Dr. Kaitin is the Director of the Tufts Center for the Study of Drug Development at Tufts University, where he studies national and worldwide trends in pharmaceutical innovation, regulation, and public policy. He is also Assistant Professor of Pharmacology and Experimental Therapeutics at Tufts University School of Medicine. Dr. Kaitin has written extensively on factors that contribute to the slow pace and high cost of pharmaceutical R&D, and the impact of regulatory and legislative initiatives to speed drug development and approval.

Marlene Haffner, MD, MPH
Executive Director, Global Regulatory and Intelligence Policy
Amgen, Inc.

Former Director, Office of Orphan Products Development, U.S. FDA

Yogendra Kumar Gupta, MD, MNAS, MBBS
Professor and Head
Department of Pharmacology
All India Institute of Medical Sciences

Chris Israel, MBA
U.S. Coordinator for International Intellectual Property Enforcement
U.S. Department of Commerce

Zili Li, MD, MPH
Director of Clinical Research Operations and Regulatory Policy – Asia Pacific
Merck & Co., Inc.

KEYNOTE SPEAKER

Kenneth I. Kaitin, PhD
Director of the Tufts Center for the Study of Drug Development
Associate Professor of Medicine
Tufts University School of Medicine, Tufts University

Dr. Kaitin is the Director of the Tufts Center for the Study of Drug Development at Tufts University, where he studies national and worldwide trends in pharmaceutical innovation, regulation, and public policy. He is also Assistant Professor of Pharmacology and Experimental Therapeutics at Tufts University School of Medicine. Dr. Kaitin has written extensively on factors that contribute to the slow pace and high cost of pharmaceutical R&D, and the impact of regulatory and legislative initiatives to speed drug development and approval.
Please monitor the DIA website for Continuing Education information.

www.diahome.org

Learning Objectives: At the conclusion of this conference, participants should be able to:

- Summarize methods to make informed decisions about conducting clinical studies from a biopharmaceutical perspective
- Identify the data management, CMC supply chain, operational requirements and CRO infrastructure in India and China
- Discuss the regulatory requirements and implication of conducting these studies in India and China
- Explain government regulation and legal infrastructure in India and China

KEY TOPICS

- Why India and China – Emerging Markets in Biopharmaceutical Development
- Data Management, Supply Chain and Operations of Clinical Research in India and China for Biopharmaceuticals
- Strategic Outsourcing and Partnership with India and China – CRO Infrastructure, Analysis and Performance
- Drug Registration of Biopharmaceuticals/Vaccines in India and China – (Process of drug registrations)
- Government Policy and Regulatory Landscape

WEDNESDAY • APRIL 25

4:00-6:00 PM REGISTRATION

THURSDAY • APRIL 26

7:15-8:00 AM TUTORIAL REGISTRATION AND CONTINENTAL BREAKFAST

8:00-8:05 AM INTRODUCTION TO THE FACULTY
Rominder (Romi) Singh, PhD
Executive Director, Global Regulatory Affairs
Amgen, Inc.

8:05-8:35 AM TUTORIAL WORKSHOP

REGULATORY REGISTRATION IN INDIA AND CHINA: MULTINATIONAL CORPORATION (MNC) PERSPECTIVE

Raj Long
Executive Director, Asia Pacific-Intercon
Bristol Myers-Squibb Company-WWMG

This session will focus on a practical guide to understanding the regulatory aspects of biopharmaceutical regulatory applications in India and China. During the session we will focus on the following aspects: (1) a background of the biopharmaceutical markets in each country in order to better understand general regulatory philosophies; (2) provide a general regulatory overview; (3) provide detailed review of key components of the process including timing, costs, legal requirements, pre-clinical requisites, CMC requirements, and the like; and (4) new trends in the regulatory process, including adaptive trial designs.

As more pharmaceutical and biotechnology companies are going global, there is an increasing need for knowledge and understanding of regulatory requirements in various geographic regions that offer the potential for development and marketing of these products. India and China hold immense potential not only for traditional pharmaceuticals, but also for the biotechnology industry.

Despite paucity of published regulatory information regarding clinical trials and product registrations in India and China, this topic has so far received only cursory attention. This tutorial aims to provide an insight of the opportunities offered by India, and a broad overview of Indian regulatory scenario. Besides, it will offer in-depth understanding of the country’s regulatory nuances, including step-by-step guidance about data requirements to conduct clinical trials in India and China. The discussions will include regulatory challenges likely to be experienced while seeking clinical trial permissions or registration of biotech products in both India and China.

The session will then address the problems commonly encountered during the regulatory process. Lastly, the session will provide several practical suggestions on how to limit time and cost during the process.

8:35 AM-12:00 PM REGULATORY REGISTRATION IN INDIA AND CHINA

TUTORIAL INSTRUCTORS:

CHINA
Mark Engel
Chairman
Excel Pharmastudies, China

Jenny Zhang, MD, MHA
Director of Business Development
U.S. Excel PharmaStudies Inc.

INDIA
Brijesh Regal
Chief Executive Officer
Apothecaries Limited India

11:00 AM-1:00 PM MEETING REGISTRATION

12:00-1:00 PM LUNCH

LUNCH ON DAY ONE IS NOT PROVIDED
1:00-1:15 PM  WELCOME AND OPENING REMARKS
Romi Singh, PhD
Executive Director, Global Regulatory Affairs
Amgen, Inc.

1:15-2:00 PM  KEYNOTE ADDRESS:
WHY INDIA AND CHINA? – EMERGING MARKETS IN
BIOPHARMACEUTICAL DEVELOPMENT, PART I
Kenneth I. Kaitin, PhD
Director of the Tufts Center for the Study of Drug Development
Associate Professor of Medicine
Tufts University School of Medicine
Tufts University

This keynote session will further examine the highest stakes for
clinical research in India and China in terms of profitability, patient
population, shaping economic and regulations through production
of safe and efficacious drug development.

2:00-3:00 PM  SESSION 1
IS THE CURRENT CLIMATE IN INDIA AND CHINA
CONducive TO ATTRACT WESTERN BIOTECHNOLOGY
COMPANIES?

PANEL DISCUSSANT
Kenneth I. Kaitin, PhD
Director of the Tufts Center for the Study of Drug Development
Associate Professor of Medicine
Tufts University School of Medicine
Tufts University

PANELISTS:
Marlene Haffner, MD, MPH
Executive Director, Global Regulatory and Intelligence Policy,
Amgen, Inc.
Fidela Moreno, MD
Executive Director, Global Development Operations, Asia
and Latin America, Amgen, Inc.
Zili Li, MD, MPH
Director of Clinical Research Operations and Regulatory Policy
Merck & Co., Inc.
Yogendra Kumar Gupta, MD, MNAMS, MBBS
Professor and Head
Department of Pharmacology
All India Institute of Medical Sciences, New Delhi
Romi Singh, PhD
Executive Director, Global Regulatory Affairs
Amgen, Inc.

Speaker (China Representative)
Speaker (India Representative)

3:00-3:30 PM  REFRESHMENT BREAK

3:30- 5:00 PM  SESSION 2
DRUG CLINICAL TRIAL EXPERIENCE: INDIA AND CHINA
CHAIRPERSON
Fidela Moreno, MD
Executive Director, Global Development Operations, Asia
and Latin America, Amgen, Inc.

Leading biopharmaceutical professionals will address their experi-
ence on conducting clinical trials in India and China and how it
impacts ROW.

CLINICAL TRIAL EXPERIENCE: GLOBAL
Fidela Moreno, MD
Executive Director, Global Development Operations, Asia
and Latin America, Amgen, Inc.

CLINICAL TRIAL EXPERIENCE: CHINA
Dayao Zhao, MD, PhD
Head of Clinical Trials
Genzyme Pharmaceuticals

CLINICAL TRIAL EXPERIENCE: INDIA
Speaker Invited

5:00-6:00 PM  NETWORKING RECEPTION

FRIDAY  APRIL 27

7:15-8:15 AM  REGISTRATION AND CONTINENTAL
BREAKFAST

8:15-8:30 AM  OPENING AND REMARKS
Mark Engel
Chairman
Excel Pharmastudies, China

8:30-10:00 AM  SESSION 3
DATA MANAGEMENT, SUPPLY CHAIN AND OPERATIONS
OF CLINICAL RESEARCH IN INDIA AND CHINA
SESSION CHAIRPERSON
Chris Lee
Executive Director
Global Regulatory Affairs and Safety Operations
Amgen, Inc.

High level experts will address the entire drug development process
including clinical trial feasibility, IRBs, clinical supplies, data man-
agement, import, export and closeout reports.

Statements made by speakers are their own opinion and not necessarily that of the organization they represent, or that of the Drug Information Association. Speakers and agenda are subject to change without notice. Recording of information, in any type of media, is prohibited at all DIA events without prior written consent from DIA.
DATA MANAGEMENT AND CLINICAL TRIALS IN CHINA
Peter Wong, MS, PhM
Director Head of Global Biometrics Application System
Head Global Clinical Document Imaging and Processing
Johnson and Johnson Pharmaceuticals

SUPPLY CHAIN
Gideon Ong
Director Regional Accounts
World Courier

HEADQUARTERS PERSPECTIVE: CHALLENGES AND OPPORTUNITIES
Speaker Invited

10:00-10:30 AM  REFRESHMENT BREAK

10:30 AM-12:00 PM  SESSION 4
REGULATORY LANDSCAPE
SESSION CHAIRPERSON
Zili Li, MD, MPH
Director of Clinical Research Operations and Regulatory Policy – Asia Pacific
Merck & Co., Inc.

This session will deliver information on government policy, regulation and pharmacovigilance. Leading industry speakers will engage and reach for high-level discussion on acceptability of foreign data, GCP inspections and pharmacovigilance.

REGULATORY LANDSCAPE OF U.S. FDA
Marlene Haffner, MD, MPH
Executive Director of Regulatory Affairs for Global Affairs
Amgen, Inc.

CLINICAL AND REGULATORY LANDSCAPE IN INDIA
Yogendra Kumar Gupta, MD, MNAMS, MBBS
Professor and Head
Department of Pharmacology
All India Institute of Medical Sciences, New Delhi

CLINICAL AND REGULATORY LANDSCAPE IN CHINA
Zili Li, MD, MPH
Director of Clinical Research Operations and Regulatory Policy – Asia Pacific
Merck & Co., Inc.

12:00-1:30 PM  LUNCH

1:30-3:00 PM  SESSION 5
STRATEGIC OUTSOURCING AND PARTNERSHIP WITH INDIA AND CHINA: CRO INFRASTRUCTURE, ANALYSIS AND PERFORMANCE
SESSION CHAIRPERSON
Romi Singh, PhD
Executive Director, Global Regulatory Affairs
Amgen, Inc.

This session will cover all aspects for CRO selection, qualification and partnership to conduct clinical trials in India and China. Case studies will be presented to help facilitate decision making on the selection of local or global CRO for clinical trial services.

INDIA CRO
Brijesh Regal
Chief Executive Officer
Apothecaries Limited India

CHINA CRO
Mark Engel
Chairman
Excel Pharmastudies, China

GLOBAL CRO
Wendy Buckland
Executive Director
Latin America and Asia, PPD Inc

3:00-3:30 PM  REFRESHMENT BREAK

3:30-5:00 PM  SESSION 6
TRADE-RELATED ASPECTS OF INTELLECTUAL PROPERTY RIGHTS (TRIPS) AND GOVERNMENT POLICIES
SESSION CHAIRPERSON
Gregory E. Kalbaugh, Esq.
Director and Counsel
Intellectual Property, Trade and Labor
U.S.-India Business Council
U.S. Chamber of Commerce

This session will address trade-related aspects of intellectual property rights, government regulation and policy, and legal infrastructure in both India and China.

TRADE-RELATED ASPECTS OF INTELLECTUAL PROPERTY RIGHTS (TRIPS) PROTECTION IN INDIA AND CHINA: CURRENT STATUS
Chris Israel, MBA
US Coordinator for International Intellectual Property Enforcement
U.S. Department of Commerce

INTELLECTUAL PROPERTY RIGHTS IN INDIA
Gregory E. Kalbaugh, Esq.
Director and Counsel
Intellectual Property, Trade and Labor
U.S.-India Business Council
U.S. Chamber of Commerce

INTELLECTUAL PROPERTY RIGHTS IN CHINA
James J. Zhu, PhD, JD
Partner
Perkins Coie, LLP

5:00 PM  CONFERENCE ADJOURNED
**WORKSHOPS**

APRIL 11-13, 2007  
QT Issues in Drug Development  
The Evolving Science, Practical Issues, and Regulatory Implications  
Washington, DC

APRIL 12-13, 2007  
Preventive Drug Development: Complexities and Challenges  
Bethesda, MD

APRIL 19-20, 2007  
Industry and Health Authority Conference on: Oligonucleotide-based Therapeutics  
Bethesda, MD

APRIL 26-27, 2007  
Clinical Research and Product Registration of Biopharmaceuticals/Vaccines in India and China  
San Diego, CA

MAY 10-11, 2007  
Protecting Human Subjects in Clinical Investigations from Design to Completion  
Washington, DC

MAY 17-18, 2007  
SPL Highlights Data Elements: Clinical and Practical Approaches  
Washington, DC

JUNE 17-21, 2007  
DIA 43rd Annual Meeting  
Atlanta, GA

OCTOBER 28-30, 2007  
DIA Canadian Annual Meeting  
Ottawa, Ontario, CANADA

**TRAINING COURSES**

APRIL 16-17, 2007  
Project Management: New Drug Product Development and Lifecycle Management  
Horsham, PA

APRIL 16-17, 2007  
Clinical Statistics for Nonstatisticians  
Philadelphia, PA

APRIL 16-18, 2007  
Drug Safety Surveillance and Epidemiology  
Philadelphia, PA

APRIL 23-26, 2007  
Regulatory Affairs – Part I: The IND Phase  
Part II: The CTD/NDA Phase  
West Chester, PA

APRIL 30-MAY 1, 2007  
European Regulatory Affairs: An In-depth Review of Registration Procedures in the European Union  
Horsham, PA

APRIL 30-MAY 2, 2007  
Fundamentals of Clinical Research Monitoring  
Chicago, IL

APRIL 30-MAY 2, 2007  
Introduction to Good Clinical Practices and Auditing  
Chicago, IL

APRIL 30-MAY 2, 2007  
Project Management  
Chicago, IL

APRIL 30-MAY 3, 2007  
The Leadership Experience  
Chicago, IL

MAY 7-9, 2007  
Advanced Topics in Clinical Research/Drug Development  
Philadelphia, PA

MAY 21, 2007  
Good Clinical Practices for the Clinical Research Professional  
Horsham, PA

MAY 21-23, 2007  
Regulatory II: The CTD/NDA Phase  
Chicago, IL

AUGUST 6-9, 2007  
Regulatory Affairs – Part I: The IND Phase  
Part II: The CTD/NDA Phase  
Boston, MA

**TRAVEL AND HOTEL**  
The most convenient airport is San Diego International Airport and attendees should make airline reservations as early as possible to ensure availability. The Omni San Diego Hotel is holding a block of rooms at the reduced rate below until April 5, 2007, for the DIA event attendees. Room availability at this rate is guaranteed only until this date or until the block is filled.

<table>
<thead>
<tr>
<th></th>
<th>Single</th>
<th>Double</th>
</tr>
</thead>
<tbody>
<tr>
<td>Single</td>
<td>$245</td>
<td>$245</td>
</tr>
<tr>
<td>Double</td>
<td>$245</td>
<td>$245</td>
</tr>
</tbody>
</table>

Please contact the Omni San Diego hotel by telephone at +1-800-THE-OMNI or 619-231-6664 and mention the DIA event. The hotel is located at 675 L Street, San Diego, California 92101, USA.

**GROUP DISCOUNTS**  
Register 3 individuals from the same company and receive complimentary registration for a 4th! All 4 individuals must register and prepay at the same time – no exceptions. DIA will apply the value of the lowest applicable fee to this complimentary registration; it does NOT include fees for optional events or DIA membership. You may substitute group participants of the same membership status at any time; however, administrative fees may be incurred. Group registration is not available online and does not apply to the already-discounted fees for government or charitable nonprofit/academia.

To take advantage of this offer, please make a copy of this registration form for EACH of the four registrants from your company. Include the names of all four group registrants on each of the forms and return them together to DIA.

**DRUG INFORMATION ASSOCIATION**  
http://www.diahome.org

**United Airlines & US Airways**  
Save through Area Pricing and Discount Fees

To obtain schedule information and the best fares, call United Airlines’s Specialized Meeting Reservations Center at 1-800-521-4041. Make sure you refer to Meeting ID Number 571AK. Dedicated reservationists are on duty 7 days a week from 8:00 AM to 10:00 PM EST.

This special offer applies to travel on domestic segments of all United Airlines, United Express, PED, and United code share flights (UA*, operated by US Airways, US Airways Express and Air Canada).

**Participants with Disabilities:**  
DIA event facilities and overnight accommodations are accessible to persons with disabilities. Services will be made available to sensory-impaired persons attending the event if requested at least 15 days prior to event. Contact the DIA office to indicate your needs.
Clinical Research and Product Registration of Biopharmaceuticals/Vaccines in India and China

Event ID #07012
Omni San Diego Hotel, San Diego, CA, USA
APRIL 26-27, 2007

Half-day Tutorial “Regulatory Registration in India and China”
April 26, 8:00 AM-12:00 PM.

KEY TOPICS

- Logistics and Operations of Clinical Research in India and China for Biopharmaceuticals
- Strategic Outsourcing and Partnership with India and China – CRO Infrastructure, Analysis and Performance
- Drug Registration of Biopharmaceuticals/Vaccines in India and China – (Process of drug registrations)
- Government Policy and Regulatory Environment

Register online or fax this page to +1-215-442-6199

CONTACT & TABLETOP EXHIBIT INFORMATION

Attendees may visit the tabletop exhibits during the event and during receptions (if applicable).

Event information: Contact Joanne Wallace at the DIA office by telephone +1-215-442-6180, fax +1-215-442-6199 or email Joanne.Wallace@diahome.org.

Tabletop exhibit information: Contact Jeff Korn, Exhibits Associate, at the DIA office by telephone +1-215-442-6184, fax +1-215-442-6199 or email Jeff.Korn@diahome.org.

For tabletop exhibit space, please check the box below.

To receive a tabletop exhibit application, please check.

GROUP DISCOUNTS (not available online or on already discounted fees)

Register 3 individuals from the same company and receive complimentary registration for a 4th! All 4 individuals must register and prepay at the same time – no exceptions. See page 5 for complete details.

REGISTRATION FORM

Do not remove mailing label. Please return this entire page.

Please check the applicable category:
☐ Academia ☐ Government ☐ Industry ☐ CSO ☐ Student (Call for registration information)

Last Name Check if part of group registration ☐ First Name ☐
☐ Dr. ☐ Mr. ☐ Ms.

Degrees

Job Title

Company

Address As required for postal delivery to your location

Mail Stop

City

State

Zip/Postal

Country

email Required for confirmation

Phone Number

Fax Number Required for confirmation

Group Registrant #2 Last Name

First Name

Completed form required for each group registrant

Group Registrant #3 Last Name

First Name

Completed form required for each group registrant

Group Registrant #4 Last Name

First Name

Completed form required for each group registrant

PAYMENT OPTIONS

Register online at www.diahome.org or check payment method

☐ CREDIT CARD number may be faxed to: +1-215-442-6199. You may prefer to pay by check or bank transfer since non-U.S. credit card payment will be subject to the currency conversion rate at the time of the charge.

☐ Visa ☐ MC ☐ AMEX

Exp Date ____________________________

Card # ____________________________

Name (printed) ____________________________

Signature ____________________________

☐ CHECK drawn on a US bank payable to and mailed along with this form to: Drug Information Association Inc, P.O. Box 95000-1240, Philadelphia, PA 19195-1240, USA. Please include a copy of this registration form to facilitate identification of attendee.

☐ BANK TRANSFER When DIA completes your registration, an email will be sent to the address on the registration form with instructions on how to complete the Bank Transfer. Payment should be made in us dollars. Your name and company, as well as the Event I.D. # must be included on the transfer document to ensure payment to your account.

GROUP DISCOUNTS

- Government (Full-time) US $ 300
- Non-U.S. Full-time US $ 430
- Charitable Nonprofit/Academia (Full-time) US $ 625
- Nonmember US $ 1150
- Nonmember US $ 130

TUTORIAL

April 26, 8:00 AM-12:00 PM Regulatory Registration in India and China

US $ 375

To receive a tabletop exhibit application, please check.

CANCELLATION POLICY:

- On or before APRIL 19, 2007
- Administrative fee that will be withheld from refund amount: Member or Nonmember = $200
- Government or Academia or Nonprofit (Member or Nonmember) = $100
- Tutorial = $50

Cancellations must be in writing and be received by the cancellation date above. Registrants who do not cancel by that date and do not attend will be responsible for the full registration fee paid. Registrants are responsible for cancelling their own hotel and airline reservations. You may transfer your registration to a colleague at any time but membership is not transferable. Please notify DIA of any such substitutions as soon as possible. Substitute registrants will be responsible for nonmember fee, if applicable.

DIA reserves the right to alter the venue, if necessary. If an event is cancelled, DIA is not responsible for any-airfare, hotel or other costs incurred by registrants.

I cannot attend but please keep me informed of DIA’s future events.

(requires completion of name, postal address and email address on this form)

MEMBER EARLY-BIRD OPPORTUNITY

Available on nondiscount member fee only.

<table>
<thead>
<tr>
<th>On or before</th>
<th>After</th>
</tr>
</thead>
<tbody>
<tr>
<td>APRIL 5, 2007</td>
<td>APRIL 5, 2007</td>
</tr>
</tbody>
</table>

MEMBER Fee

- US $ 890
- US $ 1020

Nonmember Fee

- US $ 1150
- A one-year membership to DIA is available to those paying a NONMEMBER registration fee. If paying a nonmember fee, please indicate if you do, or do not, want membership.

I want to be a DIA member ☐ I do NOT want to be a DIA member ☐

Discount Fees

<table>
<thead>
<tr>
<th>Government (Full-time)</th>
<th>Member</th>
<th>NONMEMBER*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>US $ 300</td>
<td>US $ 430</td>
</tr>
<tr>
<td>Charitable Nonprofit/Academia (Full-time)</td>
<td>US $ 625</td>
<td>US $ 755</td>
</tr>
</tbody>
</table>

*If paying a nonmember fee, please check one box above, indicating whether you want membership.

MEMBERSHIP

- US $ 130

REGISTRATION FORM

Do not remove mailing label. Please return this entire page.

07012

Please check the applicable category:

☐ Academia ☐ Government ☐ Industry ☐ CSO ☐ Student (Call for registration information)

Last Name Check if part of group registration ☐ First Name ☐
☐ Dr. ☐ Mr. ☐ Ms.

Degrees

Job Title

Company

Address As required for postal delivery to your location

Mail Stop

City

State

Zip/Postal

Country

email Required for confirmation

Phone Number

Fax Number Required for confirmation

Group Registrant #2 Last Name

First Name

Completed form required for each group registrant

Group Registrant #3 Last Name

First Name

Completed form required for each group registrant

Group Registrant #4 Last Name

First Name

Completed form required for each group registrant

PAYMENT OPTIONS

Register online at www.diahome.org or check payment method

☐ CREDIT CARD number may be faxed to: +1-215-442-6199. You may prefer to pay by check or bank transfer since non-U.S. credit card payment will be subject to the currency conversion rate at the time of the charge.

☐ Visa ☐ MC ☐ AMEX

Exp Date ____________________________

Card # ____________________________

Name (printed) ____________________________

Signature ____________________________

☐ CHECK drawn on a US bank payable to and mailed along with this form to: Drug Information Association Inc, P.O. Box 95000-1240, Philadelphia, PA 19195-1240, USA. Please include a copy of this registration form to facilitate identification of attendee.

☐ BANK TRANSFER When DIA completes your registration, an email will be sent to the address on the registration form with instructions on how to complete the Bank Transfer. Payment should be made in us dollars. Your name and company, as well as the Event I.D. # must be included on the transfer document to ensure payment to your account.

DIA is not responsible for any-airfare, hotel or other costs incurred by registrants.

I cannot attend but please keep me informed of DIA’s future events.

(requires completion of name, postal address and email address on this form)